Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

761 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studies.
Araki T, Kawahira M, Shimokawa M, Otsuka T, Hayashi K, Sonoda Y, Honda T, Nakao K, Shibuki T, Nakazawa J, Arima S, Fukahori M, Miwa K, Koga F, Ueda Y, Kubotsu Y, Makiyama A, Shimokawa H, Takeshita S, Nishikawa K, Komori A, Otsu S, Hosokawa A, Sakai T, Oda H, Arita S, Taguchi H, Tsuneyoshi K, Kawaguchi Y, Fujita T, Sakae T, Nio K, Ide Y, Ureshino N, Shirakawa T, Mizuta T, Mitsugi K. Araki T, et al. Among authors: ide y. Oncology. 2024 Oct 19:1-11. doi: 10.1159/000542137. Online ahead of print. Oncology. 2024. PMID: 39427640
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Komori A, Otsu S, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Shirakawa T, Mitsugi K. Komori A, et al. Among authors: ide y. Int J Clin Oncol. 2023 Aug;28(8):1073-1081. doi: 10.1007/s10147-023-02354-6. Epub 2023 May 20. Int J Clin Oncol. 2023. PMID: 37209158
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. Shirakawa T, et al. Among authors: ide y. Sci Rep. 2023 May 31;13(1):8815. doi: 10.1038/s41598-023-34962-7. Sci Rep. 2023. PMID: 37258608 Free PMC article.
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
Shibuki T, Otsuka T, Shimokawa M, Nakazawa J, Arima S, Fukahori M, Miwa K, Okabe Y, Koga F, Ueda Y, Kubotsu Y, Makiyama A, Shimokawa H, Takeshita S, Nishikawa K, Komori A, Otsu S, Hosokawa A, Sakai T, Oda H, Kawahira M, Arita S, Honda T, Taguchi H, Tsuneyoshi K, Kawaguchi Y, Fujita T, Sakae T, Nio K, Ide Y, Ureshino N, Shirakawa T, Mizuta T, Mitsugi K. Shibuki T, et al. Among authors: ide y. Sci Rep. 2024 Jul 23;14(1):16906. doi: 10.1038/s41598-024-65689-8. Sci Rep. 2024. PMID: 39043707 Free PMC article.
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. Shirakawa T, et al. Among authors: ide y. Sci Rep. 2024 Mar 4;14(1):5311. doi: 10.1038/s41598-024-55673-7. Sci Rep. 2024. PMID: 38438505 Free PMC article. No abstract available.
The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine-Including Biomarker Analyses.
Sugimoto N, Noura S, Kato T, Yoshioka S, Hata T, Naito A, Tei M, Tamagawa H, Komori T, Ide Y, Fukuzaki T, Danno K, Sawada G, Kagawa Y, Shimokawa T, Miyoshi N, Ogino T, Uemura M, Yamamoto H, Murata K, Doki Y, Eguchi H. Sugimoto N, et al. Among authors: ide y. Cancers (Basel). 2024 Dec 30;17(1):91. doi: 10.3390/cancers17010091. Cancers (Basel). 2024. PMID: 39796720 Free PMC article.
761 results